News & views
Our collective understanding of mental health is increasing all the time, with advances in neuroscience, psychotherapy, psychopharmacology and digital platforms.
To recognise the International Day of Education, Evie talked to us about neuroscience and her educational journey.
January 19, 2022Two thirds of physicians surveyed believe psilocybin therapy has potential benefit for patients with treatment-resistant depression
January 04, 2022A New Year message to our community
January 04, 2022COMP360 psilocybin study of 89 healthy participants published in Journal of Psychopharmacology
December 17, 2021COMPASS selected for addition to NASDAQ Biotechnology Index
December 16, 2021Our team’s highlights and reflections from 2021
"I’ve learnt that it’s important to try new things, even if they scare you."
December 16, 2021COMPASS Pathways announces changes in Executive Team
December 13, 2021COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in open-label treatment-resistant depression study
December 06, 2021George and Ekaterina at Meet Delic 2021
Video courtesy of Meet Delic
December 03, 2021Michael Falvey joins COMPASS Pathways as Chief Financial Officer
December 01, 2021COMPASS Pathways announces further positive results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression
November 23, 2021COMPASS Pathways granted fifth US patent for crystalline psilocybin
November 09, 2021COMPASS Pathways announces positive topline results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression
November 09, 2021COMPASS Pathways plc announces financial results and business highlights for the third quarter 2021
November 03, 2021COMPASS Pathways to launch phase II trial of COMP360 psilocybin therapy for post-traumatic stress disorder
October 22, 2021Our wellbeing programme at COMPASS
Anne Benedict, our Chief People Officer, talks about our approach to creating a workplace that supports mental health.
October 20, 2021Open-label study of COMP360 psilocybin therapy for depression in cancer patients demonstrates feasibility of simultaneous psilocybin administration in small groups
October 19, 2021COMPASS Pathways is granted new US patent for crystalline psilocybin
September 14, 2021COMPASS Pathways acquires IP portfolio of novel psychedelic compounds and prodrugs
September 10, 2021Hamilton Morris joins COMPASS Pathways to research new psychedelic compounds
September 08, 2021Ecosia: the search engine that plants trees
We've partnered with Ecosia to fund tree-planting projects.
August 18, 2021Completing our phase IIb clinical trial
An infographic on this significant milestone.
August 13, 2021White Paper 2021
Our White Paper looks at the state of mental health care in the US, with a focus on treatment-resistant depression.
August 11, 2021COMPASS Pathways plc announces financial results and business highlights for the second quarter 2021
July 30, 2021Learning from Plastic Free July
Our team took part in Plastic Free July, pledging to complete a variety of challenges.
July 29, 2021Guy Goodwin joins COMPASS Pathways as Chief Medical Officer
July 21, 2021Danielle Schlosser joins COMPASS Pathways from Verily Life Sciences to lead clinical innovation and therapist training
July 16, 2021Running a clinical trial during the pandemic
We speak to members of our clinical operations team to find out what it was like to run a clinical trial in the middle of COVID.
July 05, 2021COMPASS Pathways joins forces with King’s College London and South London and Maudsley NHS Foundation Trust to accelerate psychedelic research and develop new models of mental health care in the UK
June 30, 2021COMPASS Pathways launches new podcast “Everyone has a story: talking about mental health”
June 29, 2021Dr Jason Wallach talks about our Discovery Center in Philadelphia
We talk to Dr Jason Wallach, Assistant Professor of Pharmaceutical Sciences at USciences, who is leading the work with the COMPASS team.
June 28, 2021COMPASS Pathways completes COMP360 psilocybin therapy administration for 216 patients in large-scale phase IIb psilocybin therapy trial for treatment-resistant depression
June 23, 2021COMPASS Pathways becomes Founding Supporter of the British Neuroscience Association’s inaugural Scholars programme
June 11, 2021COMPASS Pathways plc to participate in JMP Securities and H.C. Wainwright investor conferences
June 03, 2021COMPASS Pathways and Kings College London publish cognition results from COMP360 psilocybin study in healthy volunteers
May 13, 2021COMPASS Pathways plc announces financial results and business highlights for the first quarter 2021
April 30, 2021COMPASS Pathways announces pricing of public offering
April 27, 2021COMPASS Pathways launches proposed public offering
April 26, 2021Elizabeth Nielson talks about our Therapist Charter
Psychologist Dr Elizabeth Nielson is a therapist on clinical trials of psilocybin-assisted treatment of alcohol use disorder, MDMA-assisted treatment of PTSD, and psilocybin-assisted treatment of treatment-resistant depression.
April 15, 2021New England Journal of Medicine publishes exploratory study showing signals of positive activity in COMP360 psilocybin compared with escitalopram for major depressive disorder
April 12, 2021COMPASS Pathways plc to participate in 20th Annual Needham Virtual Healthcare Conference
April 01, 2021COMPASS Pathways appoints Wayne J Riley MD to its Board of Directors
March 23, 2021COMPASS Pathways granted two US patents
March 09, 2021Our annual review, with a letter to our shareholders and some highlights from our year
March 09, 2021COMPASS Pathways plc announces financial results and business highlights for fourth quarter and year-end 2020
March 08, 2021The Centre of Excellence at The Sheppard Pratt Institute of Advanced Diagnostics and Therapeutics
We spoke with Scott Aaronson MD, Director of Clinical Research at Sheppard Pratt and The Centre of Excellence about this collaboration with COMPASS.
March 02, 2021The Aquilino Cancer Center
Dr Manish Agrawal tells us about an innovative investigator-initiated study in cancer patients with depression taking place at The Aquilino Cancer Center.
March 01, 2021COMPASS Pathways plc to participate in Cowen’s 41st Annual Health Care Conference
February 11, 2021The Depression and Bipolar Support Alliance
We've been working with the DBSA to better understand lived experiences of people with depression. We spoke with Phyllis Foxworth and Andrew Smith from the DBSA to learn more.
February 09, 2021COMPASS Pathways expands its Discovery Center through new collaborations with world-leading scientists
February 03, 2021COMPASS Pathways announces publication in Frontiers in Psychiatry of paper on therapist training programme for psilocybin therapy
January 28, 2021COMPASS Pathways plc to participate in Canaccord Genuity’s New Paradigms and Treatment Approaches in Mental Health Conference
January 15, 2021Inspiring future generations of diverse and inclusive scientists
Three members of our team recently spoke at an event organised by Rocking Ur Teens, a social enterprise in the UK that equips young people with the skills to become leaders.
January 14, 2021Our learning and development team
Here we speak to Archie, the newest member of our learning and development team, about the work we are doing this year to support each team member at COMPASS.
January 12, 2021Meet our green ambassadors
Here Molly and Marco, two COMPASS green ambassadors, tell us what inspires them.
January 08, 2021COMPASS Pathways establishes Centre of Excellence with Sheppard Pratt to accelerate research and improve patient experience in mental health care
January 06, 2021COMPASS Pathways plc to participate in HC Wainwright and ICR investor conferences
December 16, 2020COMPASS Pathways News | December 2020 Issue
Our highlights in the second half of 2020 as we work towards building a world of mental wellbeing for everyone.
November 30, 2020Meet Laura from the Psychiatry Consortium
We speak to Laura Arjam, our partner at the Psychiatry Consortium, about her role, the Consortium, and what inspired her to work in mental health.
November 16, 2020Meet the team at the Grady Trauma Project
Researchers from the Grady Trauma Project tell us about their research into mental health care needs and attitudes towards psychedelic therapy in marginalized and underprivileged communities
November 12, 2020COMPASS Pathways plc announces financial results for third quarter 2020
November 09, 2020COMPASS Pathways joins the Psychiatry Consortium in a collaboration to accelerate drug discovery in mental health care
November 05, 2020COMPASS Pathways plc to announce third quarter 2020 financial results on 12 November 2020
November 04, 2020COMPASS Pathways plc to participate in Berenberg and Evercore investor conferences
October 26, 2020COMPASS Pathways plc to ring Nasdaq Stock Exchange opening bell in celebration of its successful $146.6 million IPO
October 15, 2020Our first industrial placement students: Lawrence and Archie
Meet Lawrence and Archie, the first students to take part in our industrial placement scheme, as they talk about what they hope to achieve over the next year …
September 22, 2020COMPASS Pathways announces closing of initial public offering of American Depositary Shares and full exercise of underwriters’ option to purchase additional American Depositary Shares
September 18, 2020COMPASS Pathways announces pricing of upsized initial public offering
July 31, 2020Our plastic free July challenge
We hear from our COMPASS green team about how their plastic-free July challenge went, from their triumphs to their learnings for the future ...
July 30, 2020Run for Yemen: 24 miles in 24 hours
Our team member and intern, Amanda, tells us about her "24 miles in 24 hours challenge" she organised to fund-raise for the crisis in Yemen.
July 01, 2020COMPASS Pathways News | July 2020 Issue
Here are highlights of our activities in the first half of 2020 as we work towards building a world of mental wellbeing for everyone.
June 23, 2020COMPASS Pathways strengthens leadership team with appointment of Trevor Mill as Chief Development Officer
June 19, 2020Our stories: from college to career
We speak to two of our team members about their career journey, decisions they made and advice they have for people about to do the same.
June 11, 2020Looking after our mental wellbeing at work
Two members of our COMPASS wellbeing team explain how we are looking after each other's wellbeing, as we continue to work virtually.
May 11, 2020Starting a new job … virtually
We speak to four of our newest team members about their experience of starting a job virtually.
April 27, 2020COMPASS Pathways concludes successful Series B investment round
Announcement of our successful $80m Series B investment round completion.
April 22, 2020Looking after our world, one tree at a time
Our green team member, Amy Lawrence, on how planting trees in urban areas could help our mental wellbeing
April 07, 2020The experts behind our clinical trial
To recognise World Health Day, we spoke to three lead investigators from our newest trial sites about their reasons for working in mental health and how they see the future.
March 25, 2020Protecting our communities and our teams during the COVID-19 pandemic
Letter from our co-founders explaining how we have changed our work to keep people safe during this pandemic.
March 08, 2020Inspiring our next generation of women
As we embark on our mentoring journey with The Girls’ Network one of our volunteers, Molly, explains what it takes to be an effective mentor...
January 15, 2020COMPASS Pathways granted patent covering use of its psilocybin formulation in addressing treatment-resistant depression
Article discussing the granted psilocybin patent. Featuring a comment from co-founder George Goldsmith on what this means for COMPASS Pathways.
To make sure it is safe and effective in patients, psilocybin therapy needs to be approved by medical regulators, not legislators.
The cost of developing psilocybin therapy, with clinical trials in multiple countries, is significant, and involves considerable risk and resource. We think it’s an investment worth making.
Psilocybin therapy is unusual because it’s an innovative protocol that combines a medicine with psychological support.
Here we explain our full commitment to Open Science, including publishing the results from all our trials and supporting the publication of all results from independent studies that use our psilocybin.
January 07, 2020How do we train our therapists and do we require them to have personal experience with psilocybin?
Our therapist training programme has been designed by experts from the fields of psychology, psychiatry and psychedelic therapy research.
January 03, 2020COMPASS Pathways News | December 2019 Issue
Here are highlights of our activities in the second half of 2019 that we hope will move us closer to our goal of improving mental health care for as many as possible.
December 19, 2019George and Ekaterina at the CNS Summit 2019
Video courtesy of CNS Summit
December 12, 2019COMPASS Pathways and King’s College London announce results from psilocybin study in healthy volunteers
An overview of the healthy volunteer study at Kings College London, where COMPASS Pathways COMP360 (psilocybin) was found to be well tolerated.
July 23, 2019COMPASS Pathways News | July 2019 Issue
Here are highlights of our activities in the first half of 2019 that we hope will move us closer to our goal of improving mental health care for as many as possible.
December 19, 2018COMPASS Pathways News | December 2018 Issue
As 2018 draws to a close, we reflect on another busy year and share our highlights of the last few months with you.
November 11, 2018Navigating mental health: COMPASS Pathways’ psilocybin research programme
Article written for the MAPS Bulletin Winter 2018. By Ekaterina Malievskaia, MD, MSc
October 23, 2018COMPASS Pathways receives FDA Breakthrough Therapy designation for psilocybin therapy for treatment-resistant depression
COMPASS Pathways, a life sciences company dedicated to accelerating patient access to evidence-based innovation in mental health ...
July 17, 2018COMPASS Pathways News | July 2018 Issue
This is the second of regular newsletters from COMPASS, highlighting recent and forthcoming events and developments that are relevant to us, our partners and healthcare system stakeholders.
December 19, 2017COMPASS Pathways News | December 2017 Issue
The holiday season is approaching, and as we begin dreaming of festive treats and spending the holidays cocooned in thick duvets with a cup of hot chocolate in hand, I would like to reflect on our journey this past year and share a few 2017 highlights.